About SpikImm

The startup develops long-acting human monoclonal antibodies for the prophylaxis and treatment of infectious diseases in immunocompromised patients who cannot generate adequate antibody responses post-vaccination. By providing a convenient intramuscular administration, the company ensures accessible treatment options that enhance the health and well-being of vulnerable populations.

```xml <problem> Immunocompromised patients, such as transplant recipients, often exhibit inadequate responses to traditional vaccines due to immunosuppressive therapies required to prevent organ rejection. This leaves them highly vulnerable to severe viral infections, including SARS-CoV-2 and BK Virus (BKV), leading to complications and poor transplant outcomes. </problem> <solution> SpikImm develops long-acting human monoclonal antibodies (mAbs) designed to provide immediate and sustained protection against severe viral infections in immunocompromised patients. These mAbs offer a prophylactic approach for patients who cannot generate sufficient antibody responses post-vaccination. By targeting viruses such as SARS-CoV-2 and BKV, SpikImm's portfolio aims to reduce the risk of severe complications, improve transplant outcomes, and enhance the overall quality of life for vulnerable patient populations. The mAbs are administered intramuscularly, ensuring convenient and accessible treatment options. </solution> <features> - Portfolio of long-acting human monoclonal antibodies (mAbs) targeting various viruses - Prophylactic mAbs designed for immunocompromised patients with inadequate vaccine responses - Specifically targets viruses such as SARS-CoV-2 and BK Virus (BKV) - Intramuscular administration for convenient and accessible treatment - Designed to provide broad, immediate, and long-lasting protection </features> <target_audience> The primary target audience includes transplant patients (kidney and hematopoietic stem cell transplant recipients) and other immunocompromised individuals at high risk of developing severe viral infections. </target_audience> ```

What does SpikImm do?

Where is SpikImm located?

SpikImm is based in Paris, France.

How much funding has SpikImm raised?

SpikImm has raised 12110000.

Location

Paris, France

Funding

12110000

Employees

6 employees

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

SpikImm

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

spikimm.com 300+

Paris, France

Funding

Estimated Funding

$10M+

Team (5+)

No team information available.

Company Description

Problem

Immunocompromised patients, such as transplant recipients, often exhibit inadequate responses to traditional vaccines due to immunosuppressive therapies required to prevent organ rejection. This leaves them highly vulnerable to severe viral infections, including SARS-CoV-2 and BK Virus (BKV), leading to complications and poor transplant outcomes.

Solution

SpikImm develops long-acting human monoclonal antibodies (mAbs) designed to provide immediate and sustained protection against severe viral infections in immunocompromised patients. These mAbs offer a prophylactic approach for patients who cannot generate sufficient antibody responses post-vaccination. By targeting viruses such as SARS-CoV-2 and BKV, SpikImm's portfolio aims to reduce the risk of severe complications, improve transplant outcomes, and enhance the overall quality of life for vulnerable patient populations. The mAbs are administered intramuscularly, ensuring convenient and accessible treatment options.

Features

Portfolio of long-acting human monoclonal antibodies (mAbs) targeting various viruses

Prophylactic mAbs designed for immunocompromised patients with inadequate vaccine responses

Specifically targets viruses such as SARS-CoV-2 and BK Virus (BKV)

Intramuscular administration for convenient and accessible treatment

Designed to provide broad, immediate, and long-lasting protection

Target Audience

The primary target audience includes transplant patients (kidney and hematopoietic stem cell transplant recipients) and other immunocompromised individuals at high risk of developing severe viral infections.